chr17-35119534-G-T
Variant summary
Our verdict is Benign. Variant got -8 ACMG points: 1P and 9B. PP3BP6BS1BS2
The NM_002878.4(RAD51D):c.80C>A(p.Thr27Lys) variant causes a missense, splice region change. The variant allele was found at a frequency of 0.0000546 in 1,611,852 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 2/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_002878.4 missense, splice_region
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -8 ACMG points.
Transcripts
RefSeq
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
RAD51D | ENST00000345365.11 | c.80C>A | p.Thr27Lys | missense_variant, splice_region_variant | Exon 1 of 10 | 1 | NM_002878.4 | ENSP00000338790.6 | ||
ENSG00000267618 | ENST00000593039.5 | c.3+1757C>A | intron_variant | Intron 1 of 6 | 2 | ENSP00000466834.1 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152218Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.00000811 AC: 2AN: 246624Hom.: 0 AF XY: 0.0000149 AC XY: 2AN XY: 133796
GnomAD4 exome AF: 0.0000582 AC: 85AN: 1459516Hom.: 0 Cov.: 31 AF XY: 0.0000675 AC XY: 49AN XY: 726152
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152336Hom.: 0 Cov.: 32 AF XY: 0.0000403 AC XY: 3AN XY: 74488
ClinVar
Submissions by phenotype
Breast-ovarian cancer, familial, susceptibility to, 4 Uncertain:2Benign:1
- -
This sequence change replaces threonine, which is neutral and polar, with lysine, which is basic and polar, at codon 27 of the RAD51D protein (p.Thr27Lys). This variant is present in population databases (rs139642328, gnomAD 0.01%). This missense change has been observed in individual(s) with breast cancer (PMID: 35264596). ClinVar contains an entry for this variant (Variation ID: 410557). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
- -
Hereditary cancer-predisposing syndrome Uncertain:2
This missense variant replaces threonine with lysine at codon 27 of the RAD51D protein. Computational prediction suggests that this variant may not impact protein structure and function. To our knowledge, functional studies have not been reported for this variant. This variant has been reported in an individual affected with breast cancer (PMID: 35264596). This variant also has been reported in pancreatic cancer and colorectal cancer case-control studies in 9/1005 pancreatic cancer cases and 224/23705 unaffected individuals and 100/12501 colorectal cancer cases and 224/23702 unaffected individuals, respectively (PMID: 32980694, 33309985). This variant has been identified in 2/246624 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
The p.T27K variant (also known as c.80C>A), located in coding exon 1 of the RAD51D gene, results from a C to A substitution at nucleotide position 80. The threonine at codon 27 is replaced by lysine, an amino acid with similar properties. This variant has been identified in 100/12503 unselected Japanese colorectal cancer patients and in 224/23705 controls (Fujita M et al. Clin Gastroenterol Hepatol, 2020 Dec;:). This alteration was also detected in a cohort of 1663 Brazilian breast cancer patients who underwent hereditary multigene panel testing (Guindalini RSC et al. Sci Rep, 2022 Mar;12:4190). This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
Hereditary breast ovarian cancer syndrome Uncertain:2
- -
- -
not provided Uncertain:1
The RAD51D c.80C>A (p.Thr27Lys) variant has been reported in the published literature in individuals affected with breast cancer (PMID: 35264596 (2022)), colorectal cancer (PMID: 33309985 (2022)), pancreatic cancer (PMID: 32980694 (2020)), and reportedly healthy individuals (PMIDs: 33309985 (2022), 32980694 (2020)). The frequency of this variant in the general population, 0.0000081 (2/246624 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is benign. Based on the available information, we are unable to determine the clinical significance of this variant. -
not specified Benign:1
Variant summary: RAD51D c.80C>A (p.Thr27Lys) results in a non-conservative amino acid change located in the DNA recombination and repair protein Rad51-like, C-terminal (IPR013632) of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. Consensus agreement among computation tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 0.0011 in 321790 control chromosomes. The observed variant frequency is approximately 9 fold of the estimated maximal expected allele frequency for a pathogenic variant in RAD51D causing Hereditary Breast And Ovarian Cancer Syndrome phenotype (0.00013). c.80C>A has been reported in the literature in individuals affected with Hereditary Breast And Ovarian Cancer Syndrome, without strong evidence for causality (Guindalini_2022). A large case-control study evaluating Biliary tract cancer risk reported the variant insignificantly distributed between cases and controls (Guindalini_2022). These report(s) do not provide unequivocal conclusions about association of the variant with Hereditary Breast And Ovarian Cancer Syndrome. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publications have been ascertained in the context of this evaluation (PMID: 35264596, 36243179). ClinVar contains an entry for this variant (Variation ID: 410557). Based on the evidence outlined above, the variant was classified as likely benign. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at